Franz Hackl

1.1k total citations
24 papers, 877 citations indexed

About

Franz Hackl is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Franz Hackl has authored 24 papers receiving a total of 877 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Hepatology, 16 papers in Epidemiology and 7 papers in Rheumatology. Recurrent topics in Franz Hackl's work include Hepatitis C virus research (17 papers), Liver Disease Diagnosis and Treatment (14 papers) and Hepatitis B Virus Studies (6 papers). Franz Hackl is often cited by papers focused on Hepatitis C virus research (17 papers), Liver Disease Diagnosis and Treatment (14 papers) and Hepatitis B Virus Studies (6 papers). Franz Hackl collaborates with scholars based in Austria, Slovakia and United Kingdom. Franz Hackl's co-authors include Christian Datz, Alfred Gangl, Rudolf Stauber, Michael Gschwantler, Peter Ferenci, Wolfgang Vogel, Wolfgang Jessner, Petra Steindl‐Munda, Péter Ferenci and Markus Peck‐Radosavljevic and has published in prestigious journals such as Gastroenterology, Hepatology and Journal of Hepatology.

In The Last Decade

Franz Hackl

23 papers receiving 843 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Franz Hackl Austria 12 534 508 234 234 140 24 877
D Forti Italy 20 875 1.6× 491 1.0× 33 0.1× 97 0.4× 10 0.1× 57 1.2k
Pietro Solero Italy 8 267 0.5× 213 0.4× 170 0.7× 29 0.1× 83 0.6× 9 621
Thomas Kelleher Ireland 13 292 0.5× 271 0.5× 59 0.3× 44 0.2× 40 0.3× 21 509
Fabrizio Montagnese Italy 11 343 0.6× 396 0.8× 56 0.2× 29 0.1× 41 0.3× 18 678
Marco Sciveres Italy 13 284 0.5× 261 0.5× 33 0.1× 22 0.1× 7 0.1× 51 534
Michael Tröltzsch Germany 8 180 0.3× 315 0.6× 23 0.1× 24 0.1× 10 0.1× 12 426
Michela Pasino Italy 8 411 0.8× 437 0.9× 109 0.5× 59 0.3× 87 0.6× 16 623
Haruyo Iwadate Japan 11 87 0.2× 92 0.2× 34 0.1× 35 0.1× 8 0.1× 25 316
Albert B. Hagedorn United States 12 95 0.2× 162 0.3× 120 0.5× 27 0.1× 117 0.8× 21 498
Subhash C. Gumber United States 6 270 0.5× 186 0.4× 19 0.1× 11 0.0× 35 0.3× 10 461

Countries citing papers authored by Franz Hackl

Since Specialization
Citations

This map shows the geographic impact of Franz Hackl's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Franz Hackl with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Franz Hackl more than expected).

Fields of papers citing papers by Franz Hackl

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Franz Hackl. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Franz Hackl. The network helps show where Franz Hackl may publish in the future.

Co-authorship network of co-authors of Franz Hackl

This figure shows the co-authorship network connecting the top 25 collaborators of Franz Hackl. A scholar is included among the top collaborators of Franz Hackl based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Franz Hackl. Franz Hackl is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Maieron, A, Sigrid Metz-Gercek, Franz Hackl, et al.. (2010). Antiviral treatment of chronic hepatitis C in clinical routine. Wiener klinische Wochenschrift. 122(7-8). 237–242. 2 indexed citations
2.
Maieron, A, Sigrid Metz-Gercek, Franz Hackl, et al.. (2010). Chronic hepatitis C in Austria, 1992–2006: genotype distribution and demographic factors. Eurosurveillance. 15(8). 19492–19492. 18 indexed citations
3.
Ferenci, Péter, Petra Steindl‐Munda, Wolfgang Vogel, et al.. (2005). Diagnostic Value of Quantitative Hepatic Copper Determination in Patients With Wilson’s Disease. Clinical Gastroenterology and Hepatology. 3(8). 811–818. 152 indexed citations
4.
5.
Stauber, Rudolf, Harald Hofer, Franz Hackl, et al.. (2004). Retreatment of patients with chronic hepatitis C not responding to interferon/ribavirin combination therapy with daily interferon plus ribavirin plus amantadine. Wiener klinische Wochenschrift. 116(15-16). 530–535. 4 indexed citations
6.
Jessner, Wolfgang, Rudolf Stauber, Franz Hackl, et al.. (2003). Early viral kinetics on treatment with pegylated interferon‐α‐2a in chronic hepatitis C virus genotype 1 infection*. Journal of Viral Hepatitis. 10(1). 37–42. 42 indexed citations
7.
Steindl‐Munda, Petra, Peter Ferenci, H. Brünner, et al.. (2003). Impact of high‐dose interferon induction and ribavirin therapy in patients with chronic hepatitis C relapsing after or not responding to interferon monotherapy. Liver International. 23(4). 269–275. 11 indexed citations
8.
Cauza, Edmund, Markus Peck‐Radosavljevic, H. Ulrich-Pur, et al.. (2003). Mutations of the HFE gene in patients with hepatocellular carcinoma. The American Journal of Gastroenterology. 98(2). 442–447. 38 indexed citations
9.
Ferenci, Peter, Hermann Laferl, H. Brünner, et al.. (2003). Prospective evaluation of the 24 hour interferon-induced decline in hepatitis C virus genotype 1 load to predict response to peginterferon-alfa2a/ribavirin combination therapy. Gastroenterology. 124(4). A767–A767. 6 indexed citations
10.
Angermayr, Bernhard, Manfred Cejna, F. Karnel, et al.. (2003). Survival of patients undergoing TIPS: ePTFE-covered stent-grafts vs. bare-stents. Gastroenterology. 124(4). A734–A734.
11.
Jessner, Wolfgang, Franz Hackl, Rudolf Stauber, et al.. (2002). Treatment with 40 kd pegylated (PEG)-interferon (IFN) alfa2a may overcome primary IFN-resistance in patients with chronic hepatitis C (Genotype 1). Journal of Hepatology. 36. 17–17. 1 indexed citations
12.
Ferenci, Peter, H. Brünner, Karin Nachbaur, et al.. (2001). Combination of interferon induction therapy and ribavirin in chronic hepatitis C. Hepatology. 34(5). 1006–1011. 102 indexed citations
13.
Ferenci, Peter, Rudolf Stauber, Petra Steindl‐Munda, et al.. (2001). Treatment of patients with chronic hepatitis C not responding to interferon with high-dose interferon alpha with or without ribavirin: final results of a prospective randomized trial. European Journal of Gastroenterology & Hepatology. 13(6). 699–705. 18 indexed citations
14.
Jessner, Wolfgang, et al.. (2001). Effect of pegylated (PEG 40kd) interferon (IFN)α-2a on early virus elimination in patients infected with HCV subtype 1. Gastroenterology. 120(5). A29–A29. 2 indexed citations
15.
16.
Ferenci, Peter, Rudolf Stauber, Petra Steindl‐Munda, et al.. (1999). Interim analysis of a randomized controlled trial of combination of ribavirin and high dose interferon‐α in interferon nonresponders with chronic hepatitis C. Journal of Viral Hepatitis. 6(s1). 53–58. 18 indexed citations
17.
Kazemi-Shirazi, Lili, Christian Datz, Theresia Maier-Dobersberger, et al.. (1999). The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology. 116(1). 127–134. 117 indexed citations
18.
Datz, Christian, M. R. A. LALLOZ, W. Vogel, et al.. (1997). Predominance of the HLA-H Cys282Tyr mutation in Austrian patients with genetic haemochromatosis. Journal of Hepatology. 27(5). 773–779. 71 indexed citations
19.
Vogel, Wolfgang, Ivo Graziadei, Florian Umlauft, et al.. (1996). High-dose interferon-α2b treatment prevents chronicity in acute hepatitis C. Digestive Diseases and Sciences. 41(S12). 81S–85S. 68 indexed citations
20.
Hackl, Franz & G. Schneider. (1996). Perkutane Äthanolinjektion (PEI) als Palliation bei primären hepatozellulären Karzinomen (HCC). European surgery. Supplement/European surgery. 28(2). 122–122. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D Forti Breakdown of academic impact, for papers by Pietro Solero Breakdown of academic impact, for papers by Thomas Kelleher Breakdown of academic impact, for papers by Fabrizio Montagnese Breakdown of academic impact, for papers by Marco Sciveres Breakdown of academic impact, for papers by Michael Tröltzsch Breakdown of academic impact, for papers by Michela Pasino Breakdown of academic impact, for papers by Haruyo Iwadate Breakdown of academic impact, for papers by Albert B. Hagedorn Breakdown of academic impact, for papers by Subhash C. Gumber
Rankless by CCL
2026